1. How do you define the transition from traditional AI-driven analytics to truly agentic systems in clinical research, and where do you see the most immediate impact across the trial lifecycle?
Traditional analytics describe what has happened or predict what might occur. Agentic systems go further: they reason towards a goal, select actions, and carry them out with limited supervision. The earliest gains in clinical research sit in operations, including site feasibility, document drafting, query resolution, and data reconciliation. These repetitive, rule-bound tasks suit autonomy well, as compressing them saves time without disturbing core scientific judgement.
2. Agentic AI systems are now capable of designing and dynamically adjusting trial protocols. What are the implications of this for scientific rigor, reproducibility, and regulatory acceptance?
Allowing software to shape protocols is powerful, yet it raises a difficult question: can a system-made decision be reproduced and defended to a regulator? Rigour rests on full traceability, meaning every adjustment is logged, versioned, and open to explanation. A safer path keeps these systems in a recommend-and-record role, with a person approving any protocol change. Acceptance follows from transparency, not speed. Regulators have been accepting of agentic systems in designing trial protocols, by adopting these autonomous systems for their own regulatory reviews.
3. In what ways can agentic AI transform patient recruitment strategies, particularly in improving diversity, reducing enrollment timelines, and minimizing site burden?
Patient recruitment is where autonomy makes the clearest difference. Systems can search real-world data, meaning information gathered outside formal trials, to find eligible patients from across the world, match them to sites, and surface groups that manual screening often overlooks. That widens diversity and shortens enrolment. Routine pre-screening and coordination also ease the load on sites. The limit is consent and privacy, which automation must respect rather than override.
4. With AI systems adjusting protocols and flagging safety signals in real time, how should organizations balance speed with clinical risk management and ethical accountability?
Speed and safety need not conflict when both are designed in from the start. Continuous signal detection helps; acting on those signals automatically is where care belongs. A sound model lets the system flag and rank issues, while a qualified person decides anything affecting patient safety. Responsibility must rest with a named individual, never with the software. Autonomy should cut through noise, not blur ownership.
5. The abstract highlights a lag in oversight. What governance frameworks or control mechanisms are needed to ensure safe deployment of agentic AI in clinical environments?
Governance belongs in place before deployment, not after a problem appears. That means firm limits on what a system may decide alone, audit trails for every action, validation against agreed performance thresholds, and a clear route for human escalation. Established GMP/GDP/GLP principles, the quality standards that govern regulated pharmaceutical work, offer a sensible starting point. The real gap is organizational: ownership of agentic decisions remains undefined in most companies.
6. How prepared are global regulatory bodies to evaluate and approve trials influenced or managed by agentic AI, and what changes are urgently required?
Regulators are engaging with the topic, but current frameworks still assume a person makes every meaningful choice. Bodies such as the FDA and EMA have issued considered guidance on artificial intelligence, though little of it covers systems that act on their own. The pressing need is shared definitions: what counts as an agentic decision, what evidence validates it, and how it is monitored after launch. Without that common language, approvals will trail the technology, but needless to say, the regulators are catching up.
7. What role should clinicians, data scientists, and trial managers play in supervising agentic AI systems, and where should decision-making authority ultimately reside?
Supervision splits naturally across roles. Data scientists oversee model behaviour and validation. Trial managers handle operational limits and exceptions. Clinicians govern anything touching patient safety or medical judgement, and final authority must sit with them. Agentic systems serve best as a capable colleague that proposes and completes routine work, while responsibility for serious decisions stays firmly human and clearly assigned to a named role.
8. Given that agentic AI relies heavily on real-world and historical data, how can organizations mitigate bias, ensure data quality, and maintain trust in AI-generated decisions?
Flawed inputs produce confident but flawed outputs. Historical data carries the biases of who was studied and who was left out. Mitigation starts early: diverse, well-curated data, recorded provenance, and steady monitoring for drift, the gradual decay of a model's accuracy over time. Trust grows through explanation. A clinician who cannot follow why a system made a recommendation should not act on it. Sound data controls matter more than clever models.
9. How do agentic AI systems improve pharmacovigilance compared to traditional approaches, and what are the risks of false positives or overlooked signals?
Traditional pharmacovigilance, the monitoring of drug safety once medicines are in use, tends to be manual and reactive. Agentic systems can watch several data streams at once and raise concerns far sooner. The difficulty is calibration: setting sensitivity too high creates endless false alarms, while setting it too low lets genuine signals slip through. Intelligent triage, not full automation, is the answer, with trained safety staff judging what truly matters.
10. While sponsors benefit from faster timelines and reduced operational friction, does increased autonomy risk reducing transparency or control over trial processes?
Greater autonomy can erode transparency if allowed to. Faster timelines appeal, but a sponsor unable to explain how a decision was reached has swapped control for convenience. The safeguard is visibility designed in from the outset: dashboards, decision logs, and clear points of override. Autonomy and openness can coexist, provided openness is treated as a requirement rather than an afterthought. Sponsors should expect to see inside the system.
11. What technical and organizational barriers exist in integrating agentic AI with existing clinical trial management systems, EHRs, and data platforms?
The artificial intelligence is rarely the hard part; the connections are. Clinical data sits in separate systems, inconsistent formats, and platforms never built to communicate. Linking with clinical trial management systems and electronic health records demands interoperability work and data standards many organizations have yet to finish. The other barrier is human: teams adopt new tools only once the value is plain.
12. As AI begins to “act” rather than assist, where should the ethical boundaries be drawn, particularly in patient consent, adaptive trials, and automated decision-making?
The boundary is straightforward. Software may act on operational matters, but not on anything that alters a patient's experience without human review. Consent must stay explicit and handled by people; patients deserve to know when artificial intelligence plays a part. Within adaptive trials, a system can model options, yet changing a participant's treatment remains a medical decision. Automation should widen capacity, but never quietly displace informed human judgement.
13. With biopharma companies investing heavily in agentic AI, what measurable outcomes or KPIs should define success, and how soon can organizations expect returns?
Success is best measured in operational terms first: time saved on data cleaning and query resolution, quicker site activation, shorter enrolment, and fewer protocol deviations. These appear within months and build the confidence needed to go further. Scientific and patient-outcome gains take longer and prove harder to attribute. Organizations expecting transformation within a quarter will be disappointed; those treating agentic AI as infrastructure will see returns compound steadily.
14. Looking ahead 5–10 years, do you envision agentic AI becoming the default operating model for clinical research, or will hybrid human-AI systems remain the standard?
Hybrid working between people and machines will remain the standard, which is the right outcome. Clinical research carries human consequences that justify keeping people involved, even as systems improve. What shifts is the balance: software will handle far more of the execution, while people concentrate on judgement, ethics, and oversight. The strongest organizations will not be the most automated, but the ones that match autonomy with accountability most carefully.
Read the full article — it's free
Register with Pharma Focus America to unlock expert insights, research articles and in-depth industry analysis.
